"People living in the United States need to understand that an HIV diagnosis is not a death sentence. Thanks to tremendous medical advances, a person diagnosed with HIV today can have a very near average life expectancy."
Proposition: Amazon is to Hachette as Facebook is to all news publishers.
You know about Amazon’s dispute with book publishing giant Hachette, right? Amazon and the collective book publishing industry have been locked in a long-term war over the price of ebooks, and that’s now left the World’s Biggest Bookstore with some unusual gaps on its shelves. There is no underdog in this fight; it’s two colossal, unsympathetic combatants rolling in the mud — the Eastern Front of the online trade wars.
Over the past 2-3 years, Facebook has begun to assume an Amazon-like role in the ecosystem of online news.
There’s been this thing for ages: Content is king. Which is probably true. But, I actually think it’s kind of everything that’s wrong with…not that I’m not in love with games, but it’s part of the problem with the industry at the moment. ‘Assassin’s Creed’s’ gotta have like 800 people working on it. So, if you’re going to have 800 people because you have to make all this content then everything’s going to be built in blueprint. You need to have 800 people go in the same direction.
And so you have to go with the tried and tested game format. And it’s going to be so expensive to make that. You can’t take any risks, you’ve gotta make it exactly the same as all the other games out there. And Ubisoft do take risks and things, but the broad spectrum is pretty risky for some games. And it’s all because it’s so expensive to try something and the bar is so high to do that that I think, and actually it’s kind of an easy solution for developers to think ‘we’re going to make this big racer, we’ll put so much money into content.’
Sean Murray, managing director/founder of Hello Games, developer of No Man’s Sky on the difference between their ambitious, four-man indie project vs. a big-budget, AAA game
The whole article is worth reading. This game sounds like it could be a dream come true.
Sandra Fluke heard it when she talked about insurance coverage for birth control. Sara Brown from Boston told me she was first called it at a pool party in the fifth grade because she was wearing a bikini. Courtney Caldwell in Dallas said she was tagged with it after being sexually assaulted as a freshman in high school.
Many women I asked even said that it was not having sex that inspired a young man to start rumors that they were one.
And this is what is so confounding about the word “slut”: it’s arguably the most ubiquitous slur used against women, and yet it’s nearly impossible to define.
As Mexico City archaeologists sort through the surreal array of Aztec sacrificial skulls recently uncovered while excavating their city’s subway system, it’s worth remembering that parts of the London Underground were also tunneled, blasted, picked, and drilled through a labyrinth of plague pits and cemeteries.
So what am I? As a young person I imagined myself a sort of vengeful spirit. A schoolyard Robin Hood who attacked the strong and popular on behalf of the social outcasts. I’m 36 years old now though and I realize what I am is a bully. I may have been the one who got beat up but I sent plenty of kids home in tears. I also realize that I carried those ridiculous insecurities into adulthood. I still see people who attack me as the enemy and I strike back with the same ferocity as that seventh grader I used to be. I’m ashamed of that and embarrassed. The crazy thing is I don’t even necessarily believe the stuff I say a lot of times. It would probably be more noble if I did. The truth is I just say them to be mean. I say them because I know they will hurt. It’s pretty fucked up.
Ladies and gentlemen…we have a truly sincere apology from Mike Krahulik. I didn’t expect that of him, I really didn’t.
“In January 2012, the U.S. Food and Drug Administration approved Kalydeco, the first drug to treat the underlying cause of cystic fibrosis, after just three months of review. It was one of the fastest approvals of a new medicine in the agency’s history. Vertex Pharmaceuticals, which discovered and developed the drug, priced Kalydeco at $294,000 a year, which made it one of the world’s most expensive medicines. The company also pledged to provide it free to any patient in the United States who is uninsured or whose insurance won’t cover it. Doctors and patients enthusiastically welcomed the drug because it offers life-saving health benefits and there is no other treatment. Insurers and governments readily paid the cost. Several months later, Zaltrap was approved to treat colorectal cancer. The drug was discovered by Regeneron, an emerging biopharmaceutical company like Vertex, but sold by the French drug maker Sanofi. Though it worked no better in clinical trials than Roche’s cancer drug Avastin, which itself adds only 1.4 months to life expectancy for patients with advanced colorectal cancer, Sanofi priced Zaltrap at $11,000 a month, or twice Avastin’s price. Unexpectedly, there was resistance. Doctors at Memorial Sloan-Kettering in New York, one of the world’s leading cancer centers, decided Zaltrap wasn’t worth prescribing. They announced their decision—the first time prominent physicians anywhere had said “Enough” to the introduction of a high-priced cancer drug—on the op-ed page of the New York Times. Three weeks later Sanofi effectively dropped its price by half through rebates to doctors and hospitals. Even so, British health authorities said they would not pay for the treatment. The FDA approved 39 new drugs in 2012, the most in a decade and a half—a sign that the pharmaceutical industry may be recovering from its long fallow period. Wall Street applauded the revival, especially because many drug companies are facing patent expiration for their top-selling products and could see dwindling revenues after years of lackluster research productivity. Most of the new drugs either treated rare diseases like cystic fibrosis or were marginal improvements over existing cancer drugs. All carried extremely high price tags.”—Why New Drugs Are So Expensive | MIT Technology Review (via newsweek)
“The short story is like an exquisite painting and you might, when looking at this painting, be wondering what came before or after, but you are fully absorbed in what you’re seeing. Your gaze is fixed, and you are fully engaged. That’s the beauty of the short story.”—The Rumpus Interview with Edwidge Danticat (via therumpus)